HIV and AIDS

According to Stedman's Medical Dictionary, AIDS or Acquired Immunodeficiency Syndrome is “a deficiency of cellular immunity brought on by infection with the human immunodeficiency virus (HIV-1) and characterized by opportunistic diseases, including Pneumocystis jiroveci (formerly carinii) pneumonia, Kaposi sarcoma, oral hairy leukoplakia, cytomegalovirus disease, tuberculosis, Mycobacterium avium complex (MAC) disease, candidal esophagitis, cryptosporidiosis, isoporiasis, cryptococcosis, non-Hodgkin lymphoma, progressive multifocal leukoencephalopathy (PML), herpes zoster, and lymphoma.”¹

Research on the Th1 pathogens shows they are able spread effectively in an immunocompromised environment. This means it's possible that AIDS patients pick up substantial Th1 pathogen loads. It is further possible that it is these Th1 pathogens, which kill patients.

Viral co-infections (including Epstein-Barr virus, Human Herpes Virus 6, etc.) are found in all the diseases the Marshall ProtocolA curative medical treatment for chronic inflammatory disease. Based on the Marshall Pathogenesis. treats, but our research shows that viruses are not the proximate cause of disease.

It's ultimately the Th1 pathogens, which are to blame. Dr. Alan Cantwell has concluded that even Kaposi's sarcoma is caused by the Th1 pathogens.² Indeed, as patients on the Marshall Protocol kill their Th1 pathogens, patients report having lower viral titers to the point where viral co-infections appear to be eliminated, if not kept at bay.

Nevado et al have shown that HIV replicates with the help of the vitamin D receptor.³

HIV is unique among the pathogenic viruses in that it totally suppresses the body's generation of 1,25-dihydroxyvitamin-D and makes it easy for the chronic Th1 pathogens to proliferate. Haug et al have shown that end-stage AIDS patients have 1,25-DPrimary biologically active vitamin D hormone. Activates the vitamin D nuclear receptor. Produced by hydroxylation of 25-D. Also known as 1,25-dihydroxycholecalciferol, 1,25-hydroxyvitamin D and calcitirol. levels approaching zero.⁴

The ARF has no clinical experience with AIDS patients yet. However, we do believe it due time that 'post-HIV wasting disease', and many of the other post-HIV disease are found to be Th1 in pathogenesis.

We would argue that it would make sense for an AIDS patient to strengthen his or her immune response and that the only way to do this is to kill the Th1 pathogens which dysregulate it.

A therapeutic probeA brief trial of the Marshall Protocol to see if it will generate an immunopathological response. The "gold standard" for testing whether a patient is a good candidate for the MP. will confirm the potential efficacy of this treatment.

• Alan Cantwell speaking at LAX 2006
• Bacteriality interview with Alan Cantwell
• Trevor Marshall wrote a 2003 rapid response to the editor of Chest